Navigation Links
Takeda Launches New Subsidiary in Ecuador
Date:3/21/2013

ZURICH, Switzerland, March 21, 2013 /PRNewswire/ --

Demonstrates Takeda's long-term commitment to the Latin American market

Takeda Pharmaceuticals International GmbH ("Takeda"), today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or "the Company") will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador.

Takeda is building a leading position in Latin America. It has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, and is looking at opportunities to further expand its footprint in the region. According to IMS Health, pharmaceutical sales in Latin America totaled US$ 74.5 billion in 2012 and are expected to grow at a compound annual rate of 8%* between 2012 and 2016. Takeda plans to outgrow the market over the same period.

Ecuador is a dynamic and growing market, driven by government investment and strong oil and mining industries. The country's GDP totalled more than US$ 70 billion in 2012 while pharmaceutical sales in amounted to US$1.27 billion and are expected to continue to grow by 10% during 2013*.  

In line with the Takeda's emerging markets strategy, Takeda Ecuador is building a product portfolio based on the medical needs of the population, focusing on gastroenterology, cardiology, metabolism, oncology and respiratory diseases. The Company will initially focus on Zurcal (pantoprazole), Faktu (Policresulen, Cinchocaine hydrochloride), Alevian Duo® (Pinaverium bromide, Dimeticone) and Tecta® (pantoprazole magnesium) and its gynaecology product, Albothyl (Policresulen), which Takeda repatriated following the Nycomed acquisition.

Takeda Ecuador plans to leverage its sales platform with a steady stream of product launches from its existing portfolio and R&D pipeline.

Carlos Haro has been appointed country manager for Ecuador. He joins the Company from Sanofi, where he was the General Manager for Ecuador. He will lead the start-up team which will grow steadily as the Company expands its portfolio and enters new therapeutic areas.

"The launch of our subsidiary in Ecuador reinforces Takeda's position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market," said Norbert Oppitz , Senior Vice President, Latin America, at Takeda "This investment further demonstrates our commitment to Latin America and its growth potential. We have ambitious plans in this region and we continue to evaluate opportunities to expand our footprint."

*Data Source:© 2012 IMS Health. All rights reserved. Estimate based on Market Prognosis Global 2012-2016.  


About Takeda Pharmaceuticals International GmbH

Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda's mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence in around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Areas of focus include cardiovascular and metabolic diseases, immunology and respiratory diseases, oncology and central nervous system diseases, among others. Through the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda is available through its corporate website, http://www.takeda.com

This press release has been issued by Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.



'/>"/>
SOURCE Takeda Pharmaceuticals International GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda lanza nueva subsidiaria en Ecuador
2. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
3. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
4. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
5. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
6. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
7. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
8. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
9. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
10. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
11. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 /PRNewswire/ ... research report "In Vitro Diagnostics/IVD Market by Product ... Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious ... the global market is valued at USD 60.22 ... grow at a CAGR of 5.5% during the ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology:
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):